Oral and parenteral anticoagulants: New kids on the block
Well-documented drawbacks of traditional anticoagulants have lead to the quest for an ideal anticoagulant resulting in a surge of novel anticoagulant molecules. These newer agents directly target specific steps in coagulation cascade and include newer low molecular weight heparins (adomiparin), ultr...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Journal of Postgraduate Medicine |
Subjects: | |
Online Access: | http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=4;spage=275;epage=285;aulast=Aditya |
id |
doaj-a85c654abd2d4018b0ad31df0f63077b |
---|---|
record_format |
Article |
spelling |
doaj-a85c654abd2d4018b0ad31df0f63077b2020-11-24T22:44:52ZengWolters Kluwer Medknow PublicationsJournal of Postgraduate Medicine0022-38590972-28232012-01-0158427528510.4103/0022-3859.105448Oral and parenteral anticoagulants: New kids on the blockS AdityaWell-documented drawbacks of traditional anticoagulants have lead to the quest for an ideal anticoagulant resulting in a surge of novel anticoagulant molecules. These newer agents directly target specific steps in coagulation cascade and include newer low molecular weight heparins (adomiparin), ultra low molecular weight heparins (semuloparin, RO-14), inhibitors of activated factor II (dabigatran, AZD0837), X (rivaroxaban, apixaban, edoxaban, betrixaban), IX (REG1,2), XI (antisense oligonucleotides, BMS 262084, clavatadine A), VII/tissue factor (tifacogin, PCI 274836, and BMS 593214), V (recomodulin, solulin), VIII (TB402), dual thrombin/factor X inhibitors (EP21709, tanogitran), and newer vitamin K antagonists (tecarfarin). Direct thrombin inhibitors and Factor X inhibitors are the most clinically advanced. This article discusses the recent advances in the development of novel targets of anticoagulants. Medline, EMBASE, cochrane database, medscape, SCOPUS, and clinicaltrials.gov were searched using terms "anticoagulants", "blood coagulation inhibitors", "anticoagulants and venous thromboembolism", "anticoagulants and atrial fibrillation", and "′antithrombins." Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened.http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=4;spage=275;epage=285;aulast=AdityaApixabandabigatrannovel anticoagulantsrivaroxaban |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
S Aditya |
spellingShingle |
S Aditya Oral and parenteral anticoagulants: New kids on the block Journal of Postgraduate Medicine Apixaban dabigatran novel anticoagulants rivaroxaban |
author_facet |
S Aditya |
author_sort |
S Aditya |
title |
Oral and parenteral anticoagulants: New kids on the block |
title_short |
Oral and parenteral anticoagulants: New kids on the block |
title_full |
Oral and parenteral anticoagulants: New kids on the block |
title_fullStr |
Oral and parenteral anticoagulants: New kids on the block |
title_full_unstemmed |
Oral and parenteral anticoagulants: New kids on the block |
title_sort |
oral and parenteral anticoagulants: new kids on the block |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Postgraduate Medicine |
issn |
0022-3859 0972-2823 |
publishDate |
2012-01-01 |
description |
Well-documented drawbacks of traditional anticoagulants have lead to the quest for an ideal anticoagulant resulting in a surge of novel anticoagulant molecules. These newer agents directly target specific steps in coagulation cascade and include newer low molecular weight heparins (adomiparin), ultra low molecular weight heparins (semuloparin, RO-14), inhibitors of activated factor II (dabigatran, AZD0837), X (rivaroxaban, apixaban, edoxaban, betrixaban), IX (REG1,2), XI (antisense oligonucleotides, BMS 262084, clavatadine A), VII/tissue factor (tifacogin, PCI 274836, and BMS 593214), V (recomodulin, solulin), VIII (TB402), dual thrombin/factor X inhibitors (EP21709, tanogitran), and newer vitamin K antagonists (tecarfarin). Direct thrombin inhibitors and Factor X inhibitors are the most clinically advanced. This article discusses the recent advances in the development of novel targets of anticoagulants. Medline, EMBASE, cochrane database, medscape, SCOPUS, and clinicaltrials.gov were searched using terms "anticoagulants", "blood coagulation inhibitors", "anticoagulants and venous thromboembolism", "anticoagulants and atrial fibrillation", and "′antithrombins." Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened. |
topic |
Apixaban dabigatran novel anticoagulants rivaroxaban |
url |
http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=4;spage=275;epage=285;aulast=Aditya |
work_keys_str_mv |
AT saditya oralandparenteralanticoagulantsnewkidsontheblock |
_version_ |
1725690112222691328 |